Invizyne Technologies (IZTC) Competitors $9.81 -0.21 (-2.10%) As of 07/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IZTC vs. IMMP, FENC, EDIT, SOPH, MNPR, ESPR, PRQR, SLRN, CGC, and TVGNShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Prima BioMed (IMMP), Adherex Technologies (FENC), Editas Medicine (EDIT), SOPHiA GENETICS (SOPH), Monopar Therapeutics (MNPR), Esperion Therapeutics (ESPR), ProQR Therapeutics (PRQR), Acelyrin (SLRN), Canopy Growth (CGC), and Semper Paratus Acquisition (TVGN). These companies are all part of the "pharmaceutical products" industry. Invizyne Technologies vs. Its Competitors Prima BioMed Adherex Technologies Editas Medicine SOPHiA GENETICS Monopar Therapeutics Esperion Therapeutics ProQR Therapeutics Acelyrin Canopy Growth Semper Paratus Acquisition Prima BioMed (NASDAQ:IMMP) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations. Do institutionals and insiders hold more shares of IMMP or IZTC? 2.3% of Prima BioMed shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is IMMP or IZTC more profitable? Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A Invizyne Technologies N/A N/A N/A Which has stronger valuation and earnings, IMMP or IZTC? Invizyne Technologies has lower revenue, but higher earnings than Prima BioMed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$5.14M46.88-$28.01MN/AN/AInvizyne TechnologiesN/AN/AN/AN/AN/A Does the media refer more to IMMP or IZTC? In the previous week, Prima BioMed had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Prima BioMed and 0 mentions for Invizyne Technologies. Prima BioMed's average media sentiment score of 1.87 beat Invizyne Technologies' score of 0.63 indicating that Prima BioMed is being referred to more favorably in the media. Company Overall Sentiment Prima BioMed Very Positive Invizyne Technologies Positive Do analysts recommend IMMP or IZTC? Prima BioMed currently has a consensus price target of $7.00, suggesting a potential upside of 324.24%. Given Prima BioMed's stronger consensus rating and higher possible upside, research analysts plainly believe Prima BioMed is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryPrima BioMed beats Invizyne Technologies on 8 of the 8 factors compared between the two stocks. Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.33M$209.58M$5.60B$9.10BDividend YieldN/AN/A5.24%4.00%P/E RatioN/AN/A27.9620.25Price / SalesN/A253.11429.2099.14Price / CashN/A22.4437.4658.16Price / BookN/A6.158.045.49Net IncomeN/A-$96.61M$3.18B$250.27M7 Day Performance-1.01%12.45%3.63%4.75%1 Month Performance-25.40%10.71%4.04%7.64%1 Year PerformanceN/A6.49%29.56%16.34% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$9.81-2.1%N/AN/A$61.33MN/A0.0029Gap DownIMMPPrima BioMed1.5157 of 5 stars$1.70+1.2%$7.00+311.8%-17.9%$248.27M$5.14M0.002,021FENCAdherex Technologies2.1873 of 5 stars$8.70+2.7%$13.00+49.4%+34.5%$240.12M$47.54M-17.0610News CoverageAnalyst UpgradeEDITEditas Medicine4.2751 of 5 stars$2.86+12.6%$4.70+64.3%-47.3%$239.41M$32.31M-0.94230High Trading VolumeSOPHSOPHiA GENETICS2.7371 of 5 stars$3.56+9.5%$7.00+96.6%-25.9%$237.42M$65.17M-3.56520Positive NewsMNPRMonopar Therapeutics2.0323 of 5 stars$38.37+3.1%$60.00+56.4%+924.0%$234.82MN/A-11.0310Analyst RevisionESPREsperion Therapeutics4.0385 of 5 stars$1.17+5.4%$7.00+498.3%-52.2%$231.89M$332.31M-1.46200News CoverageAnalyst RevisionPRQRProQR Therapeutics2.576 of 5 stars$2.20+2.8%$8.00+263.6%+34.1%$231.46M$20.46M-6.29180Analyst ForecastSLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135CGCCanopy Growth0.4091 of 5 stars$1.23+2.5%$2.00+62.6%-82.6%$226.16M$225.65M-0.303,150High Trading VolumeTVGNSemper Paratus Acquisition4.0446 of 5 stars$1.22+1.7%$10.00+719.7%+70.0%$224.35MN/A0.003 Related Companies and Tools Related Companies Prima BioMed Alternatives Adherex Technologies Alternatives Editas Medicine Alternatives SOPHiA GENETICS Alternatives Monopar Therapeutics Alternatives Esperion Therapeutics Alternatives ProQR Therapeutics Alternatives Acelyrin Alternatives Canopy Growth Alternatives Semper Paratus Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IZTC) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.